![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Vol. 62, Issue 1, 1-6, July 2002
Laboratory of Cell Biology, Center for Cancer Research, National
Cancer Institute, National Institutes of Health, Bethesda, Maryland
20892-4254
The human MDR1-encoded transporter is a 170-kDa plasma
membrane glycoprotein [P-glycoprotein (P-gp)] capable of binding and energy-dependent extrusion of structurally diverse organic compounds and drugs. P-gp seems to play a significant role in uptake,
distribution, and excretion of many different drugs. To determine
whether common polymorphic forms of P-gp are likely to alter function
of P-gp, we characterized five known MDR1 coding
polymorphisms (N21D, F103L, S400N, A893S, and A998T) using a vaccinia
virus-based transient expression system. Cell surface expression of
wild-type P-gp was time-dependent over a time course of 5.5 to
34.5 h; highest expression was obtained by 22 to 26.5 h after
infection/transfection, indicating that a semiquantitative assay for
P-gp expression levels was possible. HeLa cells stained with the P-gp
specific monoclonal antibodies MRK-16 and Western blots probed with
C219 revealed similar cell surface expression for the polymorphisms and
for wild-type protein. Time-dependent P-gp pump function maximal at
22 h after infection/transfection was demonstrated for the
following MDR1 fluorescence substrates: 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-pentanoic acid, succinimidyl ester (bodipy-FL)-verapamil, bodipy-FL-vinblastine, calcein-AM, bodipy-FL-prazosin, bisantrene, and bodipy-FL-forskolin, but not for daunorubicin. Transport studies of all tested substrates indicated that the substrate specificity of the pump was not
substantially affected by any of the tested polymorphisms. Cell surface
expression and function of double mutants including the more common
polymorphisms (N21D-S400N, N21D-A893S, and S400N-A893S) showed no
differences from wild-type. These results demonstrate that the common
MDR1 coding polymorphisms result in P-gps with a cell
surface distribution and function similar to wild-type P-gp.
This article has been cited by other articles:
|
|
 |
|
  J. M. Gow, L. M. Hodges, L. W. Chinn, and D. L. Kroetz Substrate-Dependent Effects of Human ABCB1 Coding Polymorphisms J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 435 - 442. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Campanero-Rhodes, A. Smith, W. Chai, S. Sonnino, L. Mauri, R. A. Childs, Y. Zhang, H. Ewers, A. Helenius, A. Imberty, et al. N-Glycolyl GM1 Ganglioside as a Receptor for Simian Virus 40 J. Virol., December 1, 2007; 81(23): 12846 - 12858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Seedhouse, M. Grundy, P. White, Y. Li, J. Fisher, D. Yakunina, A. V. Moorman, T. Hoy, N. Russell, A. Burnett, et al. Sequential Influences of Leukemia-Specific and Genetic Factors on P-Glycoprotein Expression in Blasts from 817 Patients Entered into the National Cancer Research Network Acute Myeloid Leukemia 14 and 15 Trials Clin. Cancer Res., December 1, 2007; 13(23): 7059 - 7066. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kimchi-Sarfaty, J. M. Oh, I.-W. Kim, Z. E. Sauna, A. M. Calcagno, S. V. Ambudkar, and M. M. Gottesman A "Silent" Polymorphism in the MDR1 Gene Changes Substrate Specificity Science, January 26, 2007; 315(5811): 525 - 528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Robey, Z. Zhan, R. L. Piekarz, G. L. Kayastha, T. Fojo, and S. E. Bates Increased MDR1 Expression in Normal and Malignant Peripheral Blood Mononuclear Cells Obtained from Patients Receiving Depsipeptide (FR901228, FK228, NSC630176) Clin. Cancer Res., March 1, 2006; 12(5): 1547 - 1555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Green, P. Soderkvist, P. Rosenberg, G. Horvath, and C. Peterson mdr-1 Single Nucleotide Polymorphisms in Ovarian Cancer Tissue: G2677T/A Correlates with Response to Paclitaxel Chemotherapy Clin. Cancer Res., February 1, 2006; 12(3): 854 - 859. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Rouzier, R. Rajan, P. Wagner, K. R. Hess, D. L. Gold, J. Stec, M. Ayers, J. S. Ross, P. Zhang, T. A. Buchholz, et al. Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer PNAS, June 7, 2005; 102(23): 8315 - 8320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. A. Hauser, E. Schaeffeler, S. Gauer, E. H. Scheuermann, B. Wegner, J. Gossmann, H. Ackermann, C. Seidl, B. Hocher, U. M. Zanger, et al. ABCB1 Genotype of the Donor but Not of the Recipient Is a Major Risk Factor for Cyclosporine-Related Nephrotoxicity after Renal Transplantation J. Am. Soc. Nephrol., May 1, 2005; 16(5): 1501 - 1511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E.-K. Tan, D. K.-Y. Chan, P.-W. Ng, J. Woo, Y. Y. Teo, K. Tang, L.-P. Wong, S. S. Chong, C. Tan, H. Shen, et al. Effect of MDR1 Haplotype on Risk of Parkinson Disease Arch Neurol, March 1, 2005; 62(3): 460 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Woodahl, Z. Yang, T. Bui, D. D. Shen, and R. J. Y. Ho Multidrug Resistance Gene G1199A Polymorphism Alters Efflux Transport Activity of P-Glycoprotein J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1199 - 1207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C G L Lee, K Tang, Y B Cheung, L P Wong, C Tan, H Shen, Y Zhao, R Pavanni, E J D Lee, M-C Wong, et al. MDR1, the blood-brain barrier transporter, is associated with Parkinson's disease in ethnic Chinese J. Med. Genet., May 1, 2004; 41(5): e60 - e60. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Tang, L. P. Wong, E. J.D. Lee, S. S. Chong, and C. G.L. Lee Genomic evidence for recent positive selection at the human MDR1 gene locus Hum. Mol. Genet., April 15, 2004; 13(8): 783 - 797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. G. Schuetz Lessons from the CYP3A4 Promoter Mol. Pharmacol., February 1, 2004; 65(2): 279 - 281. [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Lockhart, R. G. Tirona, and R. B. Kim Pharmacogenetics of ATP-binding Cassette Transporters in Cancer and Chemotherapy Mol. Cancer Ther., July 1, 2003; 2(7): 685 - 698. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G-T Ho, F M Moodie, and J Satsangi Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut, May 1, 2003; 52(5): 759 - 766. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
